Incidence of Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli at a Comprehensive Cancer Center in the United States
Authors:
- C.N. MihuCMC.N. Mihu
- J.J. TarrandJTJ.J. Tarrand
- K.V. RolstonKRK.V. Rolston
- 1 September 2011
- journal article
- Published by S. Karger AG in Chemotherapy
- Vol. 57 (4) , 335-338
Abstract
Background: Quinolones are used extensively for prophylaxis in high-risk cancer patients; however, increasing quinolone resistance is being reported. Extended-spectrum β-lactamase (ESBL)-producing E. coli may be associated with increased morbidity and mortality particularly in neutropenic cancer patients. Methods: We conducted a retrospective study of consecutive E. coli isolates from January 2009 to August 2009 at our institution. Data on antimicrobial susceptibility of E. coli isolates to commonly used antimicrobial agents and the frequency of ESBL production and fluoroquinolone resistance were gathered based on CLSI guidelines. Results: There were 443 isolates of E. coli recovered. The majority were from urine cultures (308 isolates, 69.5%). Forty-one (9.2%) isolates were ESBL producing. Nine (18.3%) of the 49 isolates recovered from blood stream infections were ESBL producing. Quinolone resistance was present in 204 isolates (46%). Carbapenems and aminoglycosides retained excellent activity. E. coli resistance to quinolones increasedfrom 13 to 46% in a period of 13 years (p = 0.001). Conclusion: The incidence of resistance to quinolones at our center may be increasing as a consequence of widespread use of quinolones as prophylaxis for neutropenic patients. ESBL-producing E. coli are frequent at our center and are associated with blood stream infections.Keywords
This publication has 10 references indexed in Scilit:
- Emerging Resistant Gram-Negative Aerobic Bacilli in Hospital-Acquired InfectionsChemotherapy, 2010
- Escherichia coli resistance to quinolones at a comprehensive cancer centerDiagnostic Microbiology and Infectious Disease, 2010
- Perils of quinolone exposure in cancer patientsCancer, 2010
- Prevalence and Antimicrobial Resistance Patterns of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolated from Blood Cultures in an Istanbul University HospitalChemotherapy, 2009
- Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institutionJournal of Antimicrobial Chemotherapy, 2008
- Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and NeutropeniaNew England Journal of Medicine, 2005
- Predicting Hospital Rates of Fluoroquinolone-Resistant Pseudomonas aeruginosa from Fluoroquinolone Use in US Hospitals and Their Surrounding CommunitiesClinical Infectious Diseases, 2004
- Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United StatesClinical Infectious Diseases, 2003
- Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer CenterChemotherapy, 1999
- Pseudomonas aeruginosa—Still a Frequent Pathogen in Patients with Cancer: 11‐Year Experience at a Comprehensive Cancer CenterClinical Infectious Diseases, 1999